Metabolic Complications in Korean HIV/AIDS Patients Receiving Highly Active Anti-retroviral Therapy.
- Author:
Young Ju CHOE
1
;
Sang Won PARK
;
Hong Bin KIM
;
Wan Bum PARK
;
Ki Deok LEE
;
Myoung Don OH
;
Kang Won CHOE
Author Information
1. Department of Internal Medicine, College of Medicine, Seoul National University, Seoul, Korea. mdohmd@snu.ac.kr
- Publication Type:Original Article
- Keywords:
Hyperglycemia;
Hypercholesterolemia;
Highly active anti-retroviral therapy;
HIV
- MeSH:
Antiretroviral Therapy, Highly Active;
Blood Glucose;
CD4 Lymphocyte Count;
Cholesterol;
Follow-Up Studies;
HIV;
Humans;
Hypercholesterolemia;
Hyperglycemia;
Hypertriglyceridemia;
Incidence;
Logistic Models;
Prevalence;
Protease Inhibitors;
Retrospective Studies;
Reverse Transcriptase Inhibitors;
Risk Factors;
Stavudine;
Triglycerides
- From:
Infection and Chemotherapy
2004;36(4):197-206
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Since the introduction of HAART (Highly Active Anti-Retroviral Therapy), metabolic com- plications have been reported with varying prevalence. We performed a retrospective study to evaluate the incidence and risk factors of metabolic complications arising in Korean HIV/AIDS patients. MATERIALS AND METHODS: 66 HIV positive patients on combination therapy between 1998 June to 2002 June with at least 1 protease inhibitor (PI) or/and Non-nucleoside reverse transcriptase inhibitors (NNRTI) were reviewed. Hyperglycemia was defined as serum glucose >140 mg/dL on 2 or more occasions; diabetes as any random serum glucose >200 mg/dl; hypercholesterolemia as serum cholesterol >240 mg/dL; hypertriglyceridemia as serum triglyceride >200 mg/dL. We used SPSS version 9.0 for statistical analysis. One way ANOVA was used to compare the treatment groups. Multinominal logistic regression analysis was used for risk factor analysis. RESULTS: 66 patients were analyzed and total duration of follow up was 138 patient-years. The incidence of metabolic complication was 20.3%. Incidence of hypertriglyceridemia, hypercholesterolemia, hyperglycemia, and diabetes were 12.3%, 5.8%. 1.4%, 4.3% respectively. On risk factor analysis, factors contributing to the development of metabolic complication were age>35 years (P= 0.020) and baseline serum triglyceride >140 mg/dL (P=0.001). Baseline CD4 count <170/mm3 (P= 0.054) and use of stavudine >6 months (P=0.055) were associated with development of metabolic complications with borderline significance. CONCLUSION: The incidence of metabolic complication among Korean HIV/AIDS patients receiving HAART is 20.3%. Older age and high baseline triglyceride were risk factors for development of metabolic complications.
